ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":175166456,"tweetId":"175166456","gmtCreate":1627014681275,"gmtModify":1633768756268,"author":{"id":3584671125441803,"idStr":"3584671125441803","authorId":3584671125441803,"authorIdStr":"3584671125441803","name":"Abbeyc","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>ok</p></body></html>","htmlText":"<html><head></head><body><p>ok</p></body></html>","text":"ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/175166456","repostId":1108728730,"repostType":4,"repost":{"id":"1108728730","pubTimestamp":1627012466,"share":"https://www.laohu8.com/m/news/1108728730?lang=&edition=full","pubTime":"2021-07-23 11:54","market":"us","language":"en","title":"EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight","url":"https://stock-news.laohu8.com/highlight/detail?id=1108728730","media":"investorplace","summary":"Shares of Second Sight Medical Products (NASDAQ:EYES) are setting up for a second day of double-digi","content":"<p>Shares of&nbsp;<b>Second Sight Medical Products</b>&nbsp;(NASDAQ:<b><u>EYES</u></b>) are setting up for a second day of double-digit gains after the company was granted a key patent in Europe. EYES stock is up more that 15% in premarket trading on Thursday.</p>\n<p>The stock surged 12.2% on Wednesday on more than two times theaverage daily volume&nbsp;after the&nbsp;European Patent Office granted the company’s patent applicationcovering field focusing and mapping in an electrode array that could include artificial vision.</p>\n<p>“The present invention is a system for mapping a high resolution image to a lower resolution electrode array and, by applying varying stimulus to neighboring electrodes, creating a perceived image greater in resolution than the electrode array,” the patent specification read.</p>\n<p>Second Sight’s primary focus is developing the Orion Visual Cortical Prosthesis System, which is designed to provide artificial vision to those made blind due to glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. The company also offers an implant for retinitis pigmentosa (RP).</p>\n<p>Earlier FDA Decision Sent EYES Stock Surging</p>\n<p>News in early March that the U.S. Food and Drug Administration (FDA) had given the greenlight to the company’s Argus 2s Retinal Prosthesis System sent EYES stock surging to a four-year high of $20 a share.</p>\n<p><i>InvestorPlace</i>‘sLouis Navellier noted in Marchthat Second Sight “is the kind of company that people like to root for.”</p>\n<p>“Perhaps this is because Second Sight focuses its efforts on vision restoration, which is such an important medical field. Or maybe it’s because the company has a truly compelling origin story.” One of the founders, Sam Williams,suffered from RP, he noted.</p>\n<p>Late last month, Second Sight closed on a secondary offering of 11,500,000 shares of its common stock, raising a total of $57.5 million with the transaction. It said then that it planned to use the money raised primarily for development of the Orion device and general corporate purposes.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 11:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/eyes-stock-the-artificial-vision-news-that-has-investors-looking-at-second-sight/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Second Sight Medical Products (NASDAQ:EYES) are setting up for a second day of double-digit gains after the company was granted a key patent in Europe. EYES stock is up more that 15% in ...</p>\n\n<a href=\"https://investorplace.com/2021/07/eyes-stock-the-artificial-vision-news-that-has-investors-looking-at-second-sight/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/07/eyes-stock-the-artificial-vision-news-that-has-investors-looking-at-second-sight/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108728730","content_text":"Shares of Second Sight Medical Products (NASDAQ:EYES) are setting up for a second day of double-digit gains after the company was granted a key patent in Europe. EYES stock is up more that 15% in premarket trading on Thursday.\nThe stock surged 12.2% on Wednesday on more than two times theaverage daily volume after the European Patent Office granted the company’s patent applicationcovering field focusing and mapping in an electrode array that could include artificial vision.\n“The present invention is a system for mapping a high resolution image to a lower resolution electrode array and, by applying varying stimulus to neighboring electrodes, creating a perceived image greater in resolution than the electrode array,” the patent specification read.\nSecond Sight’s primary focus is developing the Orion Visual Cortical Prosthesis System, which is designed to provide artificial vision to those made blind due to glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. The company also offers an implant for retinitis pigmentosa (RP).\nEarlier FDA Decision Sent EYES Stock Surging\nNews in early March that the U.S. Food and Drug Administration (FDA) had given the greenlight to the company’s Argus 2s Retinal Prosthesis System sent EYES stock surging to a four-year high of $20 a share.\nInvestorPlace‘sLouis Navellier noted in Marchthat Second Sight “is the kind of company that people like to root for.”\n“Perhaps this is because Second Sight focuses its efforts on vision restoration, which is such an important medical field. Or maybe it’s because the company has a truly compelling origin story.” One of the founders, Sam Williams,suffered from RP, he noted.\nLate last month, Second Sight closed on a secondary offering of 11,500,000 shares of its common stock, raising a total of $57.5 million with the transaction. It said then that it planned to use the money raised primarily for development of the Orion device and general corporate purposes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":196,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/175166456"}